Human epidermal growth factor receptor 2 (HER2) is involved in the pathogenesis and poor
outcomes of several types of cancer, including advanced gastric and gastroesophageal …

Through the recent conduct of the ToGA trial, HER2 has shown to be predictive for the
treatment with trastuzumab in advanced gastric and gastro-oesophageal cancer. When it …

Gastric cancer is the fifth most frequently diagnosed cancer and the third leading cause of
death from cancer in the world. Several advances have been made in the staging …

Purpose In Asian countries, paclitaxel once per week is used as second-line treatment in
advanced gastric cancer, including human epidermal growth factor receptor 2 (HER2) …

The NCCN Clinical Practice Guidelines in Oncology for Gastric Cancer provide evidence-
and consensus-based recommendations for a multidisciplinary approach for the …

This book is the third volume of the 4th Edition of the WHO series on histological and genetic
typing of human tumours. It is an authoritative, concise reference book providing an …

Esophageal cancer is the sixth most common cause of cancer deaths worldwide.
Adenocarcinoma is more common in North America and Western European countries …

Trastuzumab-based therapy has been shown to confer overall survival benefit in HER2-
positive patients with advanced gastric cancer in a large multicentric trial (ToGA study) …

Background: Patients with gastric cancer (GC) have a poor survival and biologicals such as
Trastuzumab have not been used routinely in these patients. Existing data on HER2 …

Gastric cancer (GC) represents a global health concern. Despite advances in prevention,
diagnosis, and therapy, GC is still the third leading cause of cancer mortality worldwide, with …